The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Export

@article{citeulike:3383637, abstract = {PURPOSE: The 70-gene prognosis-signature has shown to be a valid prognostic tool in node-negative breast cancer. Although axillary lymph node status is considered to be one of the most important prognostic factors, still 25-30\% of node-positive breast cancer patients will remain free of distant metastases, even without adjuvant systemic therapy. We therefore investigated whether the 70-gene prognosis-signature can accurately identify patients with 1-3 positive lymph nodes who have an excellent disease outcome. METHODS: Frozen tumour samples from 241 patients with operable T1-3 breast cancer, and 1-3 positive axillary lymph nodes, with a median follow-up of 7.8 years, were selected from 2 institutes. Using a customized microarray, tumour samples were analysed for the 70-gene tumour expression signature. In addition, we reanalysed part of a previously described cohort (n = 106) with extended follow-up. RESULTS: The 10-year distant metastasis-free (DMFS) and breast cancer specific survival (BCSS) probabilities were 91\% (SE 4\%) and 96\% (SE 2\%), respectively for the good prognosis-signature group (99 patients), and 76\% (SE 4\%) and 76\% (SE 4\%), respectively for the poor prognosis-signature group (142 patients). The 70-gene signature was significantly superior to the traditional prognostic factors in predicting BCSS with a multivariate hazard ratio (HR) of 7.17 (95\% CI 1.81 to 28.43; P = 0.005). CONCLUSIONS: The 70-gene prognosis-signature outperforms traditional prognostic factors in predicting disease outcome in patients with 1-3 positive nodes. Moreover, the signature can accurately identify patients with an excellent disease outcome in node-positive breast cancer, who may be safely spared adjuvant chemotherapy.}, author = {Mook, Stella and Schmidt, Marjanka K. and Viale, Giuseppe and Pruneri, Giancarlo and Eekhout, Inge and Floore, Arno and Glas, Annuska M. and Bogaerts, Jan and Cardoso, Fatima and Piccart-Gebhart, Martine J. and Rutgers, Emiel T. and Van't Veer, Laura J. and {TRANSBIG Consortium}}, citeulike-article-id = {3383637}, citeulike-linkout-0 = {http://dx.doi.org/10.1007/s10549-008-0130-2}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/18661261}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=18661261}, day = {27}, doi = {10.1007/s10549-008-0130-2}, issn = {1573-7217}, journal = {Breast cancer research and treatment}, keywords = {70-gene, breast-cancer, node-positive, transbig, validation}, month = {July}, number = {2}, pages = {295--302}, posted-at = {2009-02-16 22:01:10}, priority = {2}, title = {The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.}, url = {http://dx.doi.org/10.1007/s10549-008-0130-2}, volume = {116}, year = {2009} }

TY - JOUR ID - citeulike:3383637 L3 - citeulike-article-id:3383637 N2 - PURPOSE: The 70-gene prognosis-signature has shown to be a valid prognostic tool in node-negative breast cancer. Although axillary lymph node status is considered to be one of the most important prognostic factors, still 25-30% of node-positive breast cancer patients will remain free of distant metastases, even without adjuvant systemic therapy. We therefore investigated whether the 70-gene prognosis-signature can accurately identify patients with 1-3 positive lymph nodes who have an excellent disease outcome. METHODS: Frozen tumour samples from 241 patients with operable T1-3 breast cancer, and 1-3 positive axillary lymph nodes, with a median follow-up of 7.8 years, were selected from 2 institutes. Using a customized microarray, tumour samples were analysed for the 70-gene tumour expression signature. In addition, we reanalysed part of a previously described cohort (n = 106) with extended follow-up. RESULTS: The 10-year distant metastasis-free (DMFS) and breast cancer specific survival (BCSS) probabilities were 91% (SE 4%) and 96% (SE 2%), respectively for the good prognosis-signature group (99 patients), and 76% (SE 4%) and 76% (SE 4%), respectively for the poor prognosis-signature group (142 patients). The 70-gene signature was significantly superior to the traditional prognostic factors in predicting BCSS with a multivariate hazard ratio (HR) of 7.17 (95% CI 1.81 to 28.43; P = 0.005). CONCLUSIONS: The 70-gene prognosis-signature outperforms traditional prognostic factors in predicting disease outcome in patients with 1-3 positive nodes. Moreover, the signature can accurately identify patients with an excellent disease outcome in node-positive breast cancer, who may be safely spared adjuvant chemotherapy. IS - 2 JF - Breast cancer research and treatment SN - 1573-7217 EP - 302 TI - The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. VL - 116 SP - 295 KW - 70-gene KW - breast-cancer KW - node-positive KW - transbig KW - validation AU - Mook, Stella AU - Schmidt, Marjanka AU - Viale, Giuseppe AU - Pruneri, Giancarlo AU - Eekhout, Inge AU - Floore, Arno AU - Glas, Annuska AU - Bogaerts, Jan AU - Cardoso, Fatima AU - Piccart-Gebhart, Martine AU - Rutgers, Emiel AU - Van't Veer, Laura PY - 2009/07/27/ UR - http://dx.doi.org/10.1007/s10549-008-0130-2 ER -